Assessment of Lifestyle, Blood Pressure, Cholesterol and Glycated Hemoglobin in a Specific Population (LB1901)
Let's Get to Know Your Health Better? Assessment of Lifestyle, Blood Pressure and Cholesterol in the Population of Employees Libbs Farmacêutica LTDA.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Augusto T Figueiredo
- Phone Number: 1246 55 11 3879 2500
- Email: augusto.figueiredo@libbs.com.br
Study Contact Backup
- Name: Lara F Yokoya, Dr
- Phone Number: 1987 55 11 3879 2500
- Email: lara.faco@libbs.com.br
Study Locations
-
-
-
São Paulo, Brazil, 01140050
- Augusto Theodoro de Figueiredo
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Being an employee Libbs Farmacêutica Ltda;
Exclusion Criteria:
- not applicable
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Descriptive questionnaire
Time Frame: until December 2020
|
Descriptive information about lifestyle and family history and through exams, blood pressure and serum cholesterol values in the population of Libbs Farmacêutica Ltda employees.
|
until December 2020
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of hypercholesterolemia and arterial hypertension
Time Frame: until December 2020
|
Quantify the prevalence of hypercholesterolemia (serum total cholesterol above 200mg / dL - worst case) and hypertension (systolic blood pressure above 140mmHg or diastolic blood pressure above 90mmHg - worst case)
|
until December 2020
|
|
Glycated hemoglobin (HbA1c) values
Time Frame: until December 2020
|
Track the glycated hemoglobin (HbA1c) values of the research participants, in order to know the average blood glucose levels in the last 3 months before the day of the exam and quantify the prevalence of participants who have HbA1c above the value considered normal in literature, which is up to 5.6% (best scenario)
|
until December 2020
|
|
Data correlation
Time Frame: until December 2020
|
|
until December 2020
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LB1901
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.